Skip to content

HALO

Halozyme Therapeutics, Inc.

Revenue to net income

Key figures

MetricLast 12 months5-year CAGR
Revenue$1.8B+39.2%
Gross profit$1.5B+39.1%
Operating income$674M+26.6%
Net income$485M+19.7%
EPS$3.97+23.0%
Free cash flow$886M+64.8%